MedTrace Logo

Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel

NCT05253755 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-11-08

Study results available
· View outcomes & findings →

Summary

The purpose for this study is to assess the Safety and Efficacy of Daily Application for 4 weeks of DBI-001 Gel Versus Aqueous Gel in Subjects with Atopic Dermatitis

Conditions

Interventions

BIOLOGICAL

DBI-001

Topical application of DBI-001 gel on skin affected with atopic dermatitis.

BIOLOGICAL

Aqueous gel

Topical application of aqueous gel on skin affected with atopic dermatitis.

Sponsors & Collaborators

  • Derm Research, PLLC

    collaborator OTHER

  • Northsoundderm

    collaborator OTHER

  • Clear Dermatology

    collaborator OTHER

  • DermBiont, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-06
Primary Completion
2022-09-09
Completion
2022-09-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05253755 on ClinicalTrials.gov